Inhibrx Inc

Inhibrx — Investor Presentation (August 2023)

36 slides from Inhibrx's investor presentation, Aug 7, 2023

  1. Slide 1: Investor Presentation August 2023

    INBX Investor Presentation Outcomes Focused August 2023 Innovation Driven

  2. Slide 2: Presentation disclaimer

    2 Presentation disclaimer This presentation contains forward-looking statements. In some cases, you can identify forward-looking statements by the words “will,” “expect,” “intend,” “plan,” “objective,” “believe,” “estimate,” “potential,” “continue” and “ongoing,” or the negative of these terms, or o

  3. Slide 3: Company overview

    3 IPO in 2020 First IND in 2018 Founded in 2010 Company overview Partnerships with Industry Leaders: 165+ employees with an experienced leadership team and a deep expertise in protein engineering $192.5M Cash and cash equivalentsKey Financial Highlights: (as of 6/30/2023) 43.7M Common stock outstand

  4. Slide 4: Inhibrx's innovative approach to therapeutic discovery

    4 Inhibrx’s innovative approach to therapeutic discovery Our core belief: Our technology and protein engineering expertise enables us to efficiently identify optimal therapeutic formats bespoke to the target biology. Therapeutics tailored to disease biology Rapid and iterative optimization process M

  5. Slide 5: Pipeline

    5 Pipeline Oncology: INBRX-109 tetravalent DR5 agonist INBRX-106 hexavalent OX40 agonist INBRX-105 tetravalent PD-L1 targeted 4-1BB agonist Preclinical Phase 1 Phase 2 Phase 3 Precisely engineered valency to mediate optimal balance of efficacy and safety Registration-enabling study in chondrosarcoma

  6. Slide 6: Near term expected clinical milestones

    6 Near term expected clinical milestones 2H 2023 1H 2024 (PD-L1x41BB) Single agent data in r/r HNSCC INBRX-109 (DR5) Initial mesothelioma, Ewing sarcoma, colorectal cancer and GIST combination study data INBRX-101 (GvHD) Trial initiations for aGvHD and cGvHD INBRX-109 (DR5) Registration-enabling Pha

  7. Slide 7: INBRX-101 AATD recombinant AAT-Fc fusion protein

    INBRX-101 AATD recombinant Alpha-1 antitrypsin Fc-fusion protein (AAT-Fc) Recombinant AAT protein Plasma Donor derived AAT protein Goal: To develop a donor-independent source of AAT protein able to keep patients in the range of normal for extended periods of time Current SOC Inhibrx solution AAT

  8. Slide 8: INBRX-101 for the treatment of AATD

    8 INBRX-101 INBRX-101 for the treatment of alpha-1 antitrypsin (AAT) deficiency (AATD) Liver Hepatocytes synthesize and secrete AAT into the blood stream Lung AAT protects from lung tissue damage AAT protein inactivates neutrophil elastase thus preventing elastin degradation. AATD: Without AAT prote

  9. Slide 9: INBRX-101 for the treatment of AATD

    9 INBRX-101 INBRX-101 for the treatment of AATD AAT two recombinant human AAT proteins IgG4 Fc Sustainable supply Purified product Less frequent dosingProvides patients with normal level of protein for up to 3-4 weeks Not dependent on plasma donation Independent of risks associated with blood derive

  10. Slide 10: INBRX-101: phase 1 study design

    10 INBRX-101 INBRX-101: phase 1 study design INBRX-101 phase 1 study: open-label, multicenter, dose-escalating study Adult patients with AATD, regardless of prior treatment with augmentation therapy AAT serum concentration <11 µMa Nonsmoker N=6 N=6 N=6 40 mg/kg 80 mg/kg* 120 mg/kg* 40 mg/kg 80 mg/kg

  11. Slide 11: INBRX-101 topline results from phase 1

    11 INBRX-101 Topline results from phase 1, part 2 Parts 2: Favorable safety and tolerability profile with only mild and a few moderate AEs that were transient and fully reversible with minimal or no symptomatic care Dose related increases in maximal and total exposure occurred across entirety of SAD

  12. Slide 12: INBRX-101 is present in the lung in every patient sampled

    12 INBRX-101 INDRX-101 is present in the lung in every patient sampled following IV dosing suggesting penetration to target organ 100 Day 56 IN BR X- 10 1 (μ g/ m L) 0 50 200 150 120 mg/kg 80 mg/kg naive rollover naive rollover Bronchoalveolar lavage fluid (BALF) sample collection and analysis BALF

  13. Slide 13: Modeled dose of INBRX-101 Q4W achieves AAT normal range

    13 INBRX-101 Modeled phase 2 dose of 120 mg/kg Q4W achieves AAT normal range Projected mean steady-state functional AAT levels pdAAT is only projected to achieve normal functional AAT levels for 2 – 2.5 days per weekly dose in AATD patients (9/28 days per month). INBRX-101 PK/PD modeling and simulat

  14. Slide 14: Study INBRX101-01-201: ElevAATe registration-enabling trial

    14 INBRX-101 Study INBRX101-01-201: ElevAATe INBRX-101 AATD registration-enabling trial Primary Endpoint: Mean change in avg fAAT concentration as measured by anti-neutrophil elastase capacity (ANEC) from baseline to average serum trough fAAT concentration at steady state (Ctrough,ss) Key Secondary

  15. Slide 15: INBRX-101: AATD market opportunity

    15 INBRX-101 INBRX-101: AATD market opportunity ~100K ~100K ̴40K Upside market potential from continued increased rate of diagnosis and a focus on earlier prevention of lung loss Commercial viability of therapy requires abundant supply only available via INBRX-101 Sources: KOL interviews, Sandhaus c

  16. Slide 16: INBRX-101 GvHD comparison with other therapies

    16 INBRX-101 Fred Hutch/Baxalta2 Ph1/2 (n=12) U of Michigan/CSL3 AAT +/- Prednisone Ph2 (n=40) Ef fic ac y ORR (%) at day 28 (per CIBMTR) 8/12 (67%) 26/40 (65%) CR (%) at day 28 4/12 (33%) 14/40 (35%) OS 6/12 alive 45% at 6 months Sa fe ty Grade 3+ AEs 0% 0% Most Frequent AEs “No clinical apparent t

  17. Slide 17: INBRX-109 tetravalent DR5 agonist

    INBRX-109 tetravalent DR5 agonist Previous generation Goal: To develop a more precise DR5 agonist able to selectively induce apoptosis in tumor cells Empirically selected tetravalent DR5 agonist that restricts unwanted secondary clustering DR5 agonists with limited on target effect or unwanted off t

  18. Slide 18: INBRX-109: a next generation DR5 agonist

    18 INBRX-109 INBRX-109: a next generation DR5 agonist with an optimized balance of efficacy and safety Death Receptor 5 (DR5 / TRAIL-R2) is highly expressed on tumorigenic, transformed or damaged cells but not normal cells, making DR5 a promising therapeutic target in oncology1-4 INBRX-109 character

  19. Slide 19: INBRX-109 is a potent inducer of extrinsic cell death via DR5

    19 INBRX-109 INBRX-109 is a potent inducer of extrinsic cell death via the DR5 pathway INBRX-109, a tetravalent DR5 agonist, is designed to simultaneously engage four DR5 molecules to drive enhanced clustering/signaling in tumor cells while minimizing off-target effects Apoptosis Tumor cell DR5 TRAI

  20. Slide 20: INBRX-109 is precision-engineered for optimal potency and safety

    20 INBRX-109 INBRX-109 is precision-engineered for optimal potency and safety Ab (nM) 100 InSphero 3D inSightTM human liver microtissue model: 75 50 25 1 10 100 0.1 1 10 100 75 Impact of valency on cell death: 50 25 0 Valency EC 50 (p M ) 4 62 3 1000 100 10 1 0.1 5.78x 6.35x 94.2x Impact of valency

  21. Slide 21: INBRX-109: Phase 1 trial design

    21 INBRX-109 INBRX-109: Phase 1 trial design Part 1 Part 2 Part 3 INBRX-109 single-agent dose escalation N=20 All comers 3+3 design evaluating doses of 0.3 to 30 mg/kg. INBRX-109 was well tolerated; MTD was not reached 3 mg/kg selected as RP2D INBRX 109 single-agent dose expansion Complete N=116 Ong

  22. Slide 22: Encouraging mPFS and responses in chondrosarcoma patients

    22 INBRX-109 Encouraging mPFS and clinical responses observed in Chondrosarcoma patients treated with INBRX-109 Impact of valency on DR5-mediated cell death PFS by Kaplan-Meier analysis IDHmt, isocitrate dehydrogenase 1/2 mutant; PFS, progression-free survival. a Includes 1 patient from dose- escala

  23. Slide 23: INBRX-109 Phase 2 Registration Enabling Study

    23 INBRX-109 INBRX-109 Phase 2 Registration Enabling Study Primary endpoint: Progression free survival Secondary endpoints: Overall survival, quality of life, overall response rate, duration of response, disease control rate, safety, etc. N=67*N=134* Patients Conventional chondrosarcoma, Grades 2 an

  24. Slide 24: INBRX-106 hexavalent OX40 agonist

    INBRX-106 hexavalent OX40 agonist Hexavalent OX40 agonist with enhanced clustering/signaling Bivalent OX40 agonists elicit weak downstream signals with limited clinical activity Previous generation Goal: To develop a potent OX40 agonist able to induce robust signal activation weak strong Inhibrx sol

  25. Slide 25: INBRX-106: generating robust OX40 signaling

    25 INBRX-106 INBRX-106: generating robust OX40 signaling to drive anti-tumor activity INBRX-106 is designed to boost anti-tumor T-cell activity by potently activating the OX40 co-stimulatory pathway INBRX-106 characteristics: Six OX40 sdAbs IgG Fc Hexavalent Simultaneously engage multiple OX40 to dr

  26. Slide 26: INBRX-106: mechanism of action

    26 INBRX-106 T cells NK cells Monocytes Dendritic cell Tumor T NK INBRX-106: mechanism of action T cell TCR MHC antigen Tumor cell TCR MHC antigen Tumor cell OX40 INBRX-106 The T-Cell Receptor (TCR) recognizes a tumor- associated antigen presented via MHC. In response, OX40 is upregulated on tumor r

  27. Slide 27: Higher OX40 valency drives T cell activation

    27 INBRX-106 Higher OX40 valency drives T cell activation and ability to overcome Treg suppression + Hexavalent INBRX-106 engagement drives superior co- stimulation of both CD4 and CD8 T-cells versus bi-valent OX40 mAbs + INBRX-106, but a not bivalent OX40 mAb, reduces regulatory T- cell (Treg) medi

  28. Slide 28: Valency drives OX40 agonism in CPI-resistant tumor models

    28 INBRX-106 Valency drives OX40 agonism in CPI-resistant tumor models Syngeneic B16F10 Mouse Tumor Model *INBRX-106 mouse surrogate • OX40 agonism upregulates PD-L1 expression on CD4 and CD8 T-cells supporting rationale of combination with anti-PD1 agents • Hexavalent INBRX-106-a* demonstrated sing

  29. Slide 29: INBRX-106 study design

    29 INBRX-106 INBRX-106 study design Phase 1/2 study of single agent INBRX-106 and INBRX-106 in combination with pembrolizumab in patients with locally advanced or metastatic solid tumors Durable responses with anti-PD-1 in CPI-refractory patients across multiple tumor types Well-tolerated with mild

  30. Slide 30: INBRX-105 tetravalent PD-L1 targeted 4-1BB agonist

    INBRX-105 tetravalent PD-L1 targeted 4-1BB agonist Localized 4-1BB agonist specific to PD-L1+ tissues Indiscriminate 4-1BB activation leads to a narrow therapeutic window limited by hepatotoxicity Previous generation therapy Goal: Restrict potent 4-1BB agonism to areas of high PD-L1 expression Inhib

  31. Slide 31: INBRX-105: localizing and potentiating 4-1BB pathway effects

    31 INBRX-105 INBRX-105: localizing and potentiating the anti-cancer effects of the 4-1BB pathway FC Two 4-1BB sdAbs to conditionally agonize 4-1BB while allowing 4- 1BBL binding Two PD-L1 sdAbs to target and locally antagonize PD-1 interaction Fc engineered to minimize effector function Target T cel

  32. Slide 32: INBRX-105 mechanism of action

    32 INBRX-105 INBRX-105 mechanism of action The T-Cell Receptor (TCR) recognizes a tumor-associated antigen presented via MHC. This drives upregulation of 4-1BB on tumor reactive TILs to facilitate an immune response directed towards the tumor. By crosslinking 4-1BB at sites of high PD-L1 expression,

  33. Slide 33: INBRX-105 shows improved T cell modulation

    33 INBRX-105 INBRX-105 shows improved T cell modulation over PD-L1 and 4-1BB agents alone or in combination T Cell Co-stimulation2 MHC mismatch-induced TCR signal Co-stimulation with INBRX-105 following TCR engagement yields superior T cell cytokine production. INBRX-105 is more potent and induces e

  34. Slide 34: Localizing 4-1BB agonism leads to potent anti-tumor activity

    34 INBRX-105 Localizing 4-1BB agonism to the PD-L1-rich tumor microenvironment leads to potent anti-tumor activity in mouse models MC38: PD-L1+ Tumor Model1 Dramatic increase in T cell frequency in the tumor microenvironment on Day 7 post dose of INBRX-105-a* INBRX-105-a* drives complete responses i

  35. Slide 35: INBRX-105 study design

    35 INBRX-105 INBRX-105 study design An open-Label, multicenter, dose-escalation, Phase 1/2 study of INBRX-105 and INBRX-105 in combination with pembrolizumab in patients with locally advanced or metastatic solid tumors CompleteSingle agent dose escalation N=32 Part 1 Part 2 NSCLC TPS >50% Cutaneous

  36. Slide 36: Investor Relations

    Investor Relations: Kelly Deck, CPA CFO 11025 N. Torrey Pines Road Suite 200 La Jolla, CA 92037 Office: 858.795.4260 [email protected]

Inhibrx — Investor Presentation (August 2023) on 6ix